No increased risk of fatal CV events for breast cancer patients on newer hormone therapy

(Kaiser Permanente) In a new study from Kaiser Permanente, researchers found the use of aromatase inhibitors, hormone-therapy drugs used to treat patients with breast cancer, was not associated with an increased risk of fatal cardiovascular events, including heart attacks or stroke, compared with tamoxifen, another commonly prescribed anti-cancer drug that works on hormones and which has been associated with a serious risk of stroke.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news